Efficacy and safety of pembrolizumab in patients with advanced endometrial cancer: a systematic review and meta-analysis

Efficacy and safety of pembrolizumab in patients with advanced endometrial cancer: a systematic review and meta-analysis

ObjectiveThis meta-analysis evaluated pembrolizumab monotherapy and combination therapy’s efficacy and safety in recurrent or advanced endometrial cancer (EC).MethodsWe utilized PubMed, Embase, Cochrane Library, and Web of Science databases to identify clinical trials that were used to search litera...

Full description

Saved in:

Bibliographic Details
Main Authors:	Biqiong Pan, Xiaojun Lai, Jiefang Lu, Xiaoyan Bao, Zengke Fan, Jie Sun
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Series:	Frontiers in Oncology
Subjects:	pembrolizumab monotherapy endometrial cancer meta-analysis efficacy and safety
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1511301/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Maxillary osteonecrosis linked to Pembrolizumab therapy: a case report
by: Gosselin-Rousselle Louise, et al.
Published: (2024-01-01)

Toxicity Associated with Pembrolizumab Monotherapy in Patients with Gastrointestinal Cancers: A Systematic Review of Clinical Trials
by: Nikolas Naleid, et al.
Published: (2025-01-01)

Durable Clinical Benefit after Dual Checkpoint Inhibition and Single-agent Nivolumab Following Pembrolizumab Failure in Mismatch Repair-deficient Colon Cancer
by: Yat-Fung Chow, et al.
Published: (2023-10-01)

Clinical Use of Dostarlimab in Advanced Stage and Recurrent Endometrial Cancer: Patient Selection and Perspectives
by: Bujnak AC, et al.
Published: (2025-01-01)

Phase Ib/II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (JK1201I) as second‐line monotherapy for patients with small‐cell lung cancer
by: Jieran Long, et al.
Published: (2024-09-01)

Pembrolizumab for the Treatment of Locally Advanced Cutaneous Squamous Cell Carcinoma: Patient Selection and Special Considerations
by: Stewart M, et al.
Published: (2025-02-01)

Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy
by: Jiayuan Le, et al.
Published: (2025-12-01)

Systematic review and bayesian network meta-analysis: comparative efficacy and safety of six commonly used biologic therapies for moderate-to-severe Crohn’s disease
by: Haohang Su, et al.
Published: (2025-01-01)

Case report: Low-dose radiation reverses pembrolizumab resistance in melanoma
by: Ka Hey Agnes Fong, et al.
Published: (2025-02-01)

Successful Neoadjuvant Therapy with Pembrolizumab Monotherapy for Advanced Ascending Colon Cancer
by: Chien-Tzu Huang*, et al.
Published: (2023-07-01)

Efficacy and safety of intermittent fasting for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized trials
by: Joshua Chadwick, et al.
Published: (2025-01-01)

Concomitant exposure to benzodiazepines during pembrolizumab-based therapy for advanced non-small-cell lung cancer: a propensity-score matched analysis of monitoring agency data
by: Fabrizio Nelli, et al.
Published: (2025-01-01)

Efficacy and safety of PD-1 inhibitors as second-line treatment for advanced squamous esophageal cancer: a systematic review and network meta-analysis with a focus on PD-L1 expression levels
by: Fei Yang, et al.
Published: (2025-01-01)

Endometrial polyps with bizarre stromal cells: a Benign or a low-grade lesion?
by: Musen Wang, et al.
Published: (2025-02-01)

Effectiveness and Safety of Using Standardized Treatment Protocols for Hypertension Compared to Usual Care: A Meta‐Analysis of Randomized Clinical Trials
by: Gautam Satheesh, et al.
Published: (2025-01-01)

An Open‐Label Phase II Trial of Pembrolizumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Azacitidine as Second‐Line Therapy for Advanced Head and Neck Squamous Cell Cancers
by: Vinod K. Ramani, et al.
Published: (2025-01-01)

Prevalence of occult endometrial carcinoma in patients with endometrial intraepithelial neoplasia who underwent hysterectomy
by: Waraphon Thongsang, et al.
Published: (2025-01-01)

Identifying factors for pembrolizumab eligibility in head and neck cancer
by: Satoru Miyamaru, et al.
Published: (2025-02-01)

To do or not to do? – Endometrial biopsy in younger women with abnormal uterine bleeding
by: Sandra Lynn Jaya-Bodestyne, et al.
Published: (2025-03-01)

Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer’s disease: a systematic review and network meta-analysis of randomized controlled trials
by: Wenting Cai, et al.
Published: (2025-01-01)

Comparing the efficacy of different methods in assessing cervical stromal invasion in endometrial carcinoma: a retrospective study of 2,020 patients
by: Ying Yang, et al.
Published: (2025-02-01)

Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials
by: Ji Ren, et al.
Published: (2025-01-01)

Pembrolizumab with external radiation therapy effectively controlled TMB-high unresectable recurrent parathyroid cancer: a case report with review of literature
by: Hiroshi Katoh, et al.
Published: (2024-11-01)

Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
by: Richard B. Warren, et al.
Published: (2024-11-01)

Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma
by: Yuan Yao, et al.
Published: (2025-02-01)

Safety and efficacy of intravenous thrombolysis: a systematic review and meta-analysis of 93,057 minor stroke patients
by: Mostafa Hossam El Din Moawad, et al.
Published: (2025-01-01)

Efficacy and safety of transanal endoscopic microsurgery for early rectal cancer: a meta-analysis
by: Chunqiang Wang, et al.
Published: (2025-02-01)

Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment
by: Liubov A. Tashireva, et al.
Published: (2025-01-01)

Does pregabalin offer potential as a first-line therapy for generalized anxiety disorder? A meta-analysis of efficacy, safety, and cost-effectiveness
by: Narcis Cardoner, et al.
Published: (2025-02-01)

Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma
by: Yinfang Gu, et al.
Published: (2025-02-01)

Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer
by: Ke Wang, et al.
Published: (2025-01-01)

The Effect of Autologous Platelet Rich Plasma on Endometrial Receptivity: A Narrative Review
by: Milan Stefanović, et al.
Published: (2025-01-01)

Successful Pregnancy Outcome in a Patient Treated with Pembrolizumab and Exposed to Fluoro-Deoxyglucose (<sup>18</sup>F-FDG) PET/CT: Case Report and Review of Literature
by: Anna Lucia Mastricci, et al.
Published: (2025-01-01)

Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients with advanced or metastatic urothelial carcinoma who are ineligible for platinum-based chemotherapy: a meta-analysis
by: Weiming Liang, et al.
Published: (2025-02-01)

Eculizumab treatment for Chinese patients with hemolytic paroxysmal nocturnal hemoglobinuria (PNH): efficacy and safety – a single-center study
by: Leyu Wang, et al.
Published: (2025-12-01)

Medroxyprogesterone Acetate Plus Metformin to Prevent Persistent Endometrial Hyperplasia
by: Vakkas Korkmaz, et al.
Published: (2013-08-01)

Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study
by: Filip Rob, et al.
Published: (2025-12-01)

Endometrial Receptivity–Lessons from “Omics”
by: Louie Ye, et al.
Published: (2025-01-01)

Clinical efficacy and safety of proton radiotherapy for ocular conjunctival malignancies: a systematic review and meta-analysis
by: Tingwei Zheng, et al.
Published: (2025-02-01)

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%
by: Yoshihito Kogure, MD, PhD, et al.
Published: (2025-03-01)